文献速递心胸血管麻醉

心脏与血管手术中静脉白蛋白的系统综述与荟萃分析

Intravenous albumin in cardiac and vascular surgery: a systematic review and meta-analysis.
PubMed 文献 · Br J Anaesth · 2023-12-15

该研究系统检索MEDLINE、Embase和Cochrane CENTRAL(1946年至2022年11月23日),纳入42项随机对照试验,比较静脉白蛋白与合成胶体或晶体液在心血管手术患者中的效果。15项试验(2711例心脏手术患者)显示全因死亡率风险差为0.00(95%CI -0.01至0.01,I2=0%),白蛋白组液体平衡更小、白蛋白浓度更高,但重要结局无改善且成本更高,建议限制使用。

要点

  • 静脉白蛋白与对照液体相比,心血管手术患者全因死亡率无差异(风险差0.00,95%CI -0.01至0.01)。
  • 白蛋白组液体平衡更小(平均差-0.55 L,95%CI -1.06至-0.4),白蛋白浓度更高(平均差7.77 g/L,95%CI 3.73-11.8)。
  • 重要结局无改善且成本更高,建议限制性使用静脉白蛋白。

核心结论

  • 静脉白蛋白与对照液体相比,心血管手术患者 morbidity 和 mortality 无差异,缺乏重要结局改善且成本更高,建议限制使用。

研究设计与样本

  • 系统综述与荟萃分析,纳入42项随机对照试验,检索MEDLINE、Embase和Cochrane CENTRAL从1946年至2022年11月23日。

主要发现

  • 15项试验(2711例心脏手术患者)评估死亡率,风险差0.00(95%CI -0.01至0.01,I2=0%)。
  • 9项研究(1975例患者)显示白蛋白组液体平衡更小,平均差-0.55 L(95%CI -1.06至-0.4,I2=90%)。
  • 6项研究(325例患者)显示白蛋白组白蛋白浓度更高,平均差7.77 g/L(95%CI 3.73-11.8,I2=95%)。

临床怎么用

  • 在心血管手术中,静脉白蛋白不应常规用于液体替代或预充,因其未改善重要结局且成本更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous albumin is commonly utilised in cardiovascular surgery for priming of the cardiopulmonary bypass circuit, volume replacement, or both, although the evidence to support this practice is uncertain. The aim was to compare i.v. albumin with synthetic colloids and crystalloids for paediatric and adult patients undergoing cardiovascular surgery for all-cause mortality and other perioperative outcomes. METHODS: A systematic review and meta-analysis of randomised controlled trials (RCTs) of i.v. albumin compared with synthetic colloids and crystalloids on the primary outcome of all-cause mortality was conducted. Secondary outcomes included renal failure, blood loss, duration of hospital or intensive care unit stay, cardiac index, and blood component use; subgroups were analysed by age, comparator fluid, and intended use (priming, volume, or both). We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CCRT) from 1946 to November 23, 2022. RESULTS: Of 42 RCTs, mortality was assessed in 15 trials (2711 cardiac surgery patients) and the risk difference was 0.00, 95% confidence interval (CI) -0.01 to 0.01, I2=0%. Among secondary outcomes, i.v. albumin resulted in smaller fluid balance, mean difference -0.55 L, 95% CI -1.06 to -0.4, I2=90% (nine studies, 1975 patients) and higher albumin concentrations, mean difference 7.77 g L-1, 95% CI 3.73-11.8, I2=95% (six studies, 325 patients). CONCLUSIONS: Intravenous albumin use was not associated with a difference in morbidity and mortality in patients undergoing cardiovascular surgery, when compared with comparator fluids. The lack of improvement in important outcomes with albumin and its higher cost suggests it should be used restrictively. SYSTEMATIC REVIEW PROTOCOL: PROSPERO; CRD42020171876.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Skubas NJ, Callum J, Bathla A, et al. Intravenous albumin in cardiac and vascular surgery: a systematic review and meta-analysis. Br J Anaesth. 2023. PMID: 38101966. doi:10.1016/j.bja.2023.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。